Edison Pharmaceuticals Announces Initiation of EPI-743 Phase 2B Leigh Syndrome Clinical Trial

First subject enrolled in double-blind placebo-controlled trial
MOUNTAIN VIEW, Calif., Nov. 13, 2012 /PRNewswire/ — Edison Pharmaceuticals today announced the initiation of a phase 2B study entitled, „A Phase 2B Randomized, Placebo-Controlled, Double-Blind Clinical Trial of EPI-743 in Children with Leigh Syndrome.” Four clinical trial sites have been selected in the United States: Lucile Packard Children’s Hospital, Stanford University Medical Center – Palo Alto, California; Akron Children’s Hospital – Akron, Ohio; Seattle Children’s Hospital – Seattle, Washington; and Texas Children’s Hospital, Baylor University – Houston, Texas.    więcej